Investors Watch List: Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT), Intel Corporation (NASDAQ:INTC), Netflix, Inc. (NASDAQ:NFLX), Merit Medical Systems, Inc. (NASDAQ:MMSI), Exelixis (NASDAQ:EXEL)

Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT) belongs to Healthcare sector. Its weekly performance is 14.27%. On last trading day company shares ended up $1.44. Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT) distance from 50-day simple moving average (SMA50) is 6.03%. On July 09, Neptune Technologies & Bioressources, Inc. (NASDAQ:NEPT) announces that the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) has denied Aker and Enzymotec’s (collectively the “Petitioner”) request for a rehearing of certain claims in Neptune’s ‘351 patent (U.S. Patent: 8,278,351).

Intel Corporation (NASDAQ:INTC) belongs to Technology sector. Its net profit margin is 21.10% and weekly performance is -1.03%. On last trading day company shares ended up $29.73. Intel Corporation (NASDAQ:INTC) distance from 50-day simple moving average (SMA50) is -7.31%. QNX is BlackBerry’s (BBRY) infotainment and telematics platform used in automobiles. Infotainment systems control the communication and entertainment systems in a vehicle. During its conference call to announce fiscal 1Q16 earnings, BlackBerry’s management noted that it had signed a deal with Intel Corporation (NASDAQ:INTC), which chose QNX for its smart car initiative.

On 13 July, Netflix, Inc. (NASDAQ:NFLX) belongs to Services sector. Its net profit margin is 4.10% and weekly performance is 6.89%. On last trading day company shares ended up $707.61. Netflix, Inc. (NASDAQ:NFLX) distance from 50-day simple moving average (SMA50) is 12.40%. Netflix, Inc. (NASDAQ:NFLX) stock rocketed to a record high after getting a bullish endorsement from Goldman Sachs. Goldman Sachs analyst Heath Terry reiterated a buy rating on Netflix stock and raised his price target to 780 from 620. In a research report, Terry said Netflix is set to replicate its streaming video success around the world over the next two years.

Merit Medical Systems, Inc. (NASDAQ:MMSI) ended the last trading day at $21.95. Company weekly volatility is calculated as 1.84% and price to cash ratio as 97.62. Merit Medical Systems, Inc. (NASDAQ:MMSI) showed a weekly performance of 2.43%. On July 06, Merit Medical Systems, Inc. (NASDAQ:MMSI) announced that the Company will release its financial results for the second quarter ended June 30, 2015, after the close of the stock market on Thursday, July 23, 2015.Merit will hold its investor conference call on the same day (Thursday, July 23, 2015) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).

Exelixis, Inc. (NASDAQ:EXEL) belongs to Healthcare sector. Its weekly performance is 7.98%. On last trading day company shares ended up $3.79. Exelixis, Inc. (NASDAQ:EXEL) distance from 50-day simple moving average (SMA50) is 11.48%. Exelixis, Inc. (NASDAQ:EXEL) announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus ipilimumab in patients with advanced/metastatic urothelial (bladder) and other genitourinary tumors. The primary endpoint of the trial is the determination of dose-limiting toxicities (DLT) and a recommended phase 2 dose (RP2D) for the combination of cabozantinib and nivolumab, and separately, for the combination of cabozantinib, nivolumab and ipilimumab, in patients with genitourinary solid tumors. Secondary endpoints include evaluating the activity of the two combinations by objective response rate, as well as progression-free survival (PFS) and overall survival (OS), in cohorts of patients with urothelial carcinoma of the bladder, urethra, ureter or renal pelvis.

Leave a Reply

Your email address will not be published. Required fields are marked *